Current Opinion in Urology was launched in 1991. It is one of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The field of urology is divided into 12 sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Editors of the journal and the Section Editors for this issue.
Michael Marberger, MD, FRCS (ed), is a native of Innsbruck, Austria. He graduated from medical school there and completed his residency in urology at the Innsbruck University Hospital. From 1973 to 1980 he served as staff member at the Department of Urology, University of Mainz, Germany and from 1980 to 1990 as Urologist-in-Chief of the Department of Urology, Rudolfstiftung, Vienna, Austria. From 1 January 1990 until 31 September 2011 he was Professor and Chairman of the Department of Urology of the University of Vienna Medical School, Austria. He now is Professor emeritus at this institution.
Dr Marberger has published over 600 articles in peer reviewed journals and edited five text books on Urology. He is currently Editor-in-Chief of Current Opinion in Urology and on the editorial boards of several major urological journals. He serves/served as officer on the boards of major international professional societies such as the EAU, the SIU and the Endourology Society. He received numerous awards, among them: the Dr.h.c. of the Semmelweis University Budapest; the Honorary Fellowship of the Royal College of Surgeons of Edinburgh; the SIU - Yamanouchi/Astellas Lifetime Achievement Award; the “Willy Gregoir Medal” of the European Association of Urology; the “St. Paul's Medal” of the British Association of Urological Surgeons; the Certificate of Achievement Award of the American Association of Urology; the ESOU Life Time Achievement Award of the EAU Section of Oncological Urology; and the “Harry M. Spence Medal” of the American Association of Genitourinary Surgeons. He is an honorary member of 20 Urological Societies, among them the American Urological Association, Canadian Urological Association, German Association of Urology, Australasian Society of Urology, Urological Association of Asia, Dutch Urological Association and the South African Urological Association. He was Congress President of the 2006 and 2011 EAU-Congresses in Vienna.
Johannes W. Vieweg
Johannes W. Vieweg, MD, FACS is Professor and Founding Chairman of the Department of Urology and Executive Director of the Prostate Disease Center at the University of Florida (UF), Gainesville, Florida, USA. He also holds the Huizenga Eminent Scholar Endowed Chair in Urologic Oncology at UF and is an attending surgeon at the Malcom Randall VA Medical Center, USA. The American Urological Association Foundation has recently appointed him to the position of Research Council Chair. Dr Vieweg received his medical degree from the Technical University of Munich, Germany and began his residency training at the University of Ulm, Department of Urology, Germany. After relocating to the United States, he received three years of postdoctoral training at Memorial Sloan-Kettering Cancer Center, New York, USA, prior to completing his urology residency training at Duke University Medical Center, Durham, North Carolina, USA. After a nine-year tenure on the Duke urology faculty, he joined the University of Florida in July 2006.
Dr Vieweg is an internationally recognized authority in urologic oncology and has a longstanding, focused interest in cancer immunology and gene-based therapies. In addition to his administrative and clinical responsibilities, he is spearheading a productive research program focusing on the development of novel treatments for patients with advanced urologic malignancies. Dr Vieweg's projects also involve the development and testing of “targeted therapeutics”, as well as improved prediction models for therapeutic success. Reflective of the quality of his research program are numerous manuscripts published in outstanding peer-reviewed journals and continuous NIH funding for over twelve years.
Dr Djavan's clinical practice and research has focused on urologic oncology and prostatic disease. He has served as a visiting professor and guest lecturer at over 45 institutions throughout North America, Europe and Asia and is an honorary member of the Indonesian, Mexican, Georgian, Romanian and many other Urological Societies. Dr Djavan is currently Director of Minimal Invasive Prostate Cancer Research Center at NYU and Chairman of The Regional Office of the European Association of Urology (EAU). He still holds the position of a Professor of Urology at the University of Vienna, Austria, and Honorary Professorships at University of Oslo, Norway, and Moscow, Russia.
Dr Djavan has held numerous international research grants on uro-oncology and prostatic disease and has authored over 250 articles and book chapters. He holds two patents, including one for the Vienna Nomograms. Dr Djavan has received numerous awards for his research, including the Crystal Matula Award of the European Association of Urology and the Felix Guillon Award of the French Association of Urology.
Dr Djavan serves as the Associate Editor of the Canadian Journal of Urology and is on the editorial board of Urology, World Journal of Urology, Prostate Cancer and Prostatic Disease, Clinical Genitourinary Cancer, Reviews in Urology, Journal of Men's Health, Current Urology Reports, Therapeutic Advances in Urology and Urohealth. He serves as a reviewer for numerous journals, including JAMA, BMJ and Cancer.
Dr Djavan is a member of the American Urological Association, the European Association of Urology (EAU), the Societé International d’Urologie and the New York Academy of Sciences. He is a member of the Board of the European Society of Oncological Urology (ESOU), the Board of the European School of Urology (ESU), the Board of Examiners of the EAU and the WHO Task Force on Prostate Cancer.
Jim Hu, MD, MPH is an Associate Professor of Urology and Director of Robotic and Minimally Invasive Surgery in the Department of Urology, David Geffen School of Medicine at UCLA, USA. He attended Baylor College of Medicine, USA, for his MD and Johns Hopkins, USA, for his MPH, and he completed his urology training at UCLA and fellowship training at City of Hope National Medical Center, USA. Dr Hu is known internationally for his expertise in robotic-assisted surgery, particularly in regard to technical modifications to improve peri-operative and long-term outcomes for men with prostate cancer. In addition, he has published extensively on comparative effectiveness and cost analyses of open versus robotic assisted surgeries.